EP2081575A4 - ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR - Google Patents

ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR

Info

Publication number
EP2081575A4
EP2081575A4 EP07864306A EP07864306A EP2081575A4 EP 2081575 A4 EP2081575 A4 EP 2081575A4 EP 07864306 A EP07864306 A EP 07864306A EP 07864306 A EP07864306 A EP 07864306A EP 2081575 A4 EP2081575 A4 EP 2081575A4
Authority
EP
European Patent Office
Prior art keywords
adenosine receptor
allosteric modulators
allosteric
modulators
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07864306A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2081575A2 (en
Inventor
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/938,465 external-priority patent/US7855209B2/en
Priority claimed from US11/938,514 external-priority patent/US7897596B2/en
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of EP2081575A2 publication Critical patent/EP2081575A2/en
Publication of EP2081575A4 publication Critical patent/EP2081575A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP07864306A 2006-11-13 2007-11-13 ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR Withdrawn EP2081575A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85850506P 2006-11-13 2006-11-13
US11/938,465 US7855209B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
US11/938,514 US7897596B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
PCT/US2007/084490 WO2008063984A2 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor

Publications (2)

Publication Number Publication Date
EP2081575A2 EP2081575A2 (en) 2009-07-29
EP2081575A4 true EP2081575A4 (en) 2010-01-06

Family

ID=39430473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07864306A Withdrawn EP2081575A4 (en) 2006-11-13 2007-11-13 ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR

Country Status (9)

Country Link
EP (1) EP2081575A4 (enExample)
JP (1) JP2010509402A (enExample)
KR (1) KR20090112627A (enExample)
AU (1) AU2007323888A1 (enExample)
BR (1) BRPI0718520A2 (enExample)
CA (1) CA2669447A1 (enExample)
IL (1) IL198402A0 (enExample)
MX (1) MX2009004763A (enExample)
WO (1) WO2008063984A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739588B (zh) * 2014-01-04 2015-07-01 新发药业有限公司 一种2-氨基噻吩衍生物的简便合成方法
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
WO2017046794A1 (en) 2015-09-14 2017-03-23 The National Institute for Biotechnology in the Negev Ltd. Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction
US10787423B2 (en) 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
JP7365237B2 (ja) 2017-03-21 2023-10-19 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ－２受容体の新規調節物質およびその使用方法
EP3600289A4 (en) 2017-03-21 2020-08-05 Temple University - Of The Commonwealth System of Higher Education 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021617A2 (en) * 1997-10-29 1999-05-06 Medco Research, Inc. Allosteric adenosine receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
ES2092737T3 (es) * 1992-10-29 1996-12-01 Hoechst Ag Procedimiento para la preparacion de compuestos bromometil-aromaticos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021617A2 (en) * 1997-10-29 1999-05-06 Medco Research, Inc. Allosteric adenosine receptor modulators

Also Published As

Publication number Publication date
IL198402A0 (en) 2010-02-17
JP2010509402A (ja) 2010-03-25
AU2007323888A1 (en) 2008-05-29
WO2008063984A3 (en) 2008-08-14
BRPI0718520A2 (pt) 2013-11-19
CA2669447A1 (en) 2008-05-29
WO2008063984A2 (en) 2008-05-29
KR20090112627A (ko) 2009-10-28
EP2081575A2 (en) 2009-07-29
MX2009004763A (es) 2009-05-21

Similar Documents

Publication Publication Date Title
PL2038290T3 (pl) Modulatory receptora Toll-podobnego 7
ZA200900959B (en) Benzofuro-and benzothienopyrylmidine modulators of the histamine H4 receptor
IL197015A0 (en) Benzotriazole kinase modulators
EP2179061A4 (en) GREAT LIKE RECEPTOR MODULATORS
IL198990A0 (en) Cb1 receptor modulators
IL194814A0 (en) Mglur5 modulators i
IL191766A0 (en) Gaba-b receptor modulators
IL197722A0 (en) Mglur5 modulators
GB0701992D0 (en) Grehlin Receptor Modulators
ZA200807237B (en) Modulators of muscarinic receptors
EP2200595A4 (en) THIENO AND FURO PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR
IL198402A0 (en) Allosteric modulators of the a1 adenosine receptor
GB0625196D0 (en) Modulators of cannabinoid receptor
EP2222676A4 (en) A1-adenosine receptor antagonistic
IL184532A0 (en) Novel adenosine a3 receptor modulators
IL209007A0 (en) Allosteric enhancers of the a1 adenosine receptor
ZA200806237B (en) Cannibinoid receptor modulators
IL197365A0 (en) Pyridooxazepine progesteron receptor modulators
GB0622569D0 (en) Cannabinoid receptor modulators
PL2491964T3 (pl) Powłoka elastomeryczna
ZA200904663B (en) CB1 receptor modulators
GB2436727B (en) Improved fixing
ZA200907546B (en) New progesterone receptor modulators
HK1122811A (en) Cannibinoid receptor modulators
GB0608516D0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20091203

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101AFI20090514BHEP

Ipc: A61P 9/04 20060101ALI20091127BHEP

Ipc: C07D 491/113 20060101ALI20091127BHEP

Ipc: C07D 487/10 20060101ALI20091127BHEP

Ipc: C07D 487/08 20060101ALI20091127BHEP

Ipc: C07D 409/12 20060101ALI20091127BHEP

Ipc: C07D 487/04 20060101ALI20091127BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130601